Drucken
Artikel, Notizen und Markierungen werden geladen... Bitte um etwas Geduld.

Ordinance
on Clinical Trials
with the exception of
Clinical Trials of Medical Devices1
(Clinical Trials Ordinance, ClinO)

of 20 September 2013 (Status as of 26 May 2022)

1 Amended by Annex 2 No 2 of the O of 1 July 2020 on Clinical Trials with Medical Devices, in force since 26 May 2021 (AS 2020 3033).

Art. 36 Clinical trials of medicinal products or products under Article 2 a paragraph 2 TPA capable of emitting ionising radiation

1 For Cat­egory B and C clin­ic­al tri­als of medi­cin­al products or products un­der Art­icle 2a para­graph 2 TPA cap­able of emit­ting ion­ising ra­di­ation, the doc­u­ments spe­cified in An­nex 4 num­ber 5 must ad­di­tion­ally be sub­mit­ted to the Agency.

2 In the case of Cat­egory C clin­ic­al tri­als, the Agency shall seek an opin­ion from the FOPH be­fore grant­ing au­thor­isa­tion. The FOPH shall re­view com­pli­ance with ra­di­olo­gic­al pro­tec­tion le­gis­la­tion and the dose es­tim­a­tion.

3 The Agency shall grant au­thor­isa­tion if:

a.
the re­quire­ments covered by Art­icle 32 are met; and
b.
the FOPH has raised no ob­jec­tions to the clin­ic­al tri­al.

4 The Agency shall reach a de­cision on Cat­egory C clin­ic­al tri­als with­in 60 days of ac­know­ledge­ment of re­ceipt of the form­ally cor­rect ap­plic­a­tion doc­u­ments. It shall in­form the FOPH of its de­cision.

5 In the case of Cat­egory C clin­ic­al tri­als, it shall trans­mit to the FOPH dir­ectly after re­ceipt:

a.
the fi­nal re­port spe­cified in Art­icle 38 para­graph 3 in­clud­ing all in­form­a­tion of rel­ev­ance for ra­di­olo­gic­al pro­tec­tion, and in par­tic­u­lar a ret­ro­spect­ive par­ti­cipant dose es­tim­a­tion, un­less stip­u­la­tions to the con­trary have been made by the FOPH;
b.
the re­ports spe­cified in Art­icle 41 para­graph 2 and Art­icle 42 para­graph 1.